Diagnosis and Management of Acral Lentiginous Melanoma

Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response

(2018) Yoshiyuki Nakamura et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

(2017) Omid Hamid et al.   EUROPEAN JOURNAL OF CANCER

Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan

(2017) Maiko Wada et al.   JOURNAL OF DERMATOLOGY

Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features

(2017) Emily A Merkel et al.   LABORATORY INVESTIGATION

Melanoma subtypes demonstrate distinct PD-L1 expression profiles

(2017) Genevieve J Kaunitz et al.   LABORATORY INVESTIGATION

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

(2017) Mark B. Faries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD1 signal transduction pathways in T cells

(2017) Hugo Arasanz et al.   Oncotarget

Excision Margins for Melanoma In Situ on the Head and Neck

(2016) Sarah Felton et al.   DERMATOLOGIC SURGERY

Surgical excision margin for primary acral melanoma

(2016) Kyeong-Tae Lee et al.   JOURNAL OF SURGICAL ONCOLOGY

NCCN Guidelines Insights: Melanoma, Version 3.2016

(2016) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

(2016) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod

(2016) Richard W. Joseph et al.   MELANOMA RESEARCH

Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma

(2016) Andrew J. Marek et al.   JAMA Dermatology

Nail Melanoma In Situ

(2015) Ana F. Duarte et al.   DERMATOLOGIC SURGERY

Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type

(2015) Susan M. Swetter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma

(2015) Soo Young Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Acral lentiginous melanoma: Who benefits from sentinel lymph node biopsy?

(2015) Takamichi Ito et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

BRAF V600 mutations and pathological features in Japanese melanoma patients

(2015) Naoya Yamazaki et al.   MELANOMA RESEARCH

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade and Interferon-α in Melanoma

(2015) Imran Rafique et al.   SEMINARS IN ONCOLOGY

Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells

(2014) I. Savarese et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot

(2013) B.H. Oh et al.   BRITISH JOURNAL OF DERMATOLOGY

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma

(2013) Abdlsattar Zebary et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth

(2012) Alice Hervieu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma

(2012) Wesley O. Greaves et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites

(2011) K. Omholt et al.   CLINICAL CANCER RESEARCH

Comparison of Secondary Intention Healing and Full-Thickness Skin Graft After Excision of Acral Lentiginous Melanoma on Foot

(2011) JIN YOUNG JUNG et al.   DERMATOLOGIC SURGERY

Guidelines of care for the management of primary cutaneous melanoma

(2011) Christopher K. Bichakjian et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Surgical margins for melanoma in situ

(2011) Joy H. Kunishige et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics

(2010) Scott E. Woodman et al.   BIOCHEMICAL PHARMACOLOGY

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

(2010) J.-H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population

(2009) A. Phan et al.   BRITISH JOURNAL OF DERMATOLOGY

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH